These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 11724238

  • 1. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors.
    Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S, Okad Y.
    Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1457-63. PubMed ID: 11724238
    [Abstract] [Full Text] [Related]

  • 2. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship.
    Okada Y, Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S.
    Chem Pharm Bull (Tokyo); 2000 Dec; 48(12):1964-72. PubMed ID: 11145152
    [Abstract] [Full Text] [Related]

  • 3. Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines.
    Okada Y, Tsuda Y, Wanaka K, Tada M, Okamoto U, Okamoto S, Hijikata-Okunomiya A, Bokonyi G, Szende B, Keri G.
    Bioorg Med Chem Lett; 2000 Oct 02; 10(19):2217-21. PubMed ID: 11012033
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
    Teno N, Otsubo T, Gohda K, Wanaka K, Sueda T, Ikeda K, Hijikata-Okunomiya A, Tsuda Y.
    J Pept Sci; 2012 Oct 02; 18(10):620-5. PubMed ID: 22961872
    [Abstract] [Full Text] [Related]

  • 5. Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
    Rester U, Bode W, Moser M, Parry MA, Huber R, Auerswald E.
    J Mol Biol; 1999 Oct 15; 293(1):93-106. PubMed ID: 10512718
    [Abstract] [Full Text] [Related]

  • 6. Development of plasma kallikrein selective inhibitors.
    Okada Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto U, Okamoto S.
    Biopolymers; 1999 Oct 15; 51(1):41-50. PubMed ID: 10380351
    [Abstract] [Full Text] [Related]

  • 7. Similarity and dissimilarity in the stereogeometry of the active sites of thrombin, trypsin, plasmin and glandular kallikrein.
    Hijikata-Okunomiya A, Okamoto S, Kikumoto R, Tamao Y, Ohkubo K, Tezuka T, Tonomura S, Matsumoto O.
    Thromb Res; 1987 Mar 01; 45(5):451-62. PubMed ID: 2954262
    [Abstract] [Full Text] [Related]

  • 8. Active site-directed plasmin inhibitors: Extension on the P2 residue.
    Hidaka K, Gohda K, Teno N, Wanaka K, Tsuda Y.
    Bioorg Med Chem; 2016 Feb 15; 24(4):545-53. PubMed ID: 26732532
    [Abstract] [Full Text] [Related]

  • 9. Role of P225 and the C136-C201 disulfide bond in tissue plasminogen activator.
    Vindigni A, Di Cera E.
    Protein Sci; 1998 Aug 15; 7(8):1728-37. PubMed ID: 10082369
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
    Gladysz R, Adriaenssens Y, De Winter H, Joossens J, Lambeir AM, Augustyns K, Van der Veken P.
    J Med Chem; 2015 Dec 10; 58(23):9238-57. PubMed ID: 26575094
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of netropsin and pentamidine amino analogues on the amidolytic activity of plasmin, trypsin and urokinase.
    Pućkowska A, Midura-Nowaczek K, Bruzgo I.
    Acta Pol Pharm; 2008 Dec 10; 65(2):213-5. PubMed ID: 18666427
    [Abstract] [Full Text] [Related]

  • 14. Replacement of lysine by arginine, phenylalanine and tryptophan in the reactive site of the bovine trypsin-kallikrein inhibitor (Kunitz) and change of the inhibitory properties.
    Jering H, Tschesche H.
    Eur J Biochem; 1976 Jan 15; 61(2):453-63. PubMed ID: 129327
    [Abstract] [Full Text] [Related]

  • 15. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K, Jensen ON, Bugge TH, Lund LR, Ploug M, Danø K, Behrendt N.
    Biochemistry; 2000 Jan 25; 39(3):508-15. PubMed ID: 10642175
    [Abstract] [Full Text] [Related]

  • 16. Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: the importance of the peptide backbone.
    Fukumizu A, Tsuda Y, Wanaka K, Tada M, Okamoto S, Hijikata-Okunomiya A, Okada Y.
    Chem Pharm Bull (Tokyo); 1999 Aug 25; 47(8):1141-4. PubMed ID: 10478469
    [Abstract] [Full Text] [Related]

  • 17. Discovery and development of plasma kallikrein inhibitors for multiple diseases.
    Xie Z, Li Z, Shao Y, Liao C.
    Eur J Med Chem; 2020 Mar 15; 190():112137. PubMed ID: 32066009
    [Abstract] [Full Text] [Related]

  • 18. Development of plasmin-selective inhibitors and studies of their structure-activity relationship.
    Okada Y, Matsumoto Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto S.
    Chem Pharm Bull (Tokyo); 2000 Feb 15; 48(2):184-93. PubMed ID: 10705502
    [Abstract] [Full Text] [Related]

  • 19. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N, Moroi M, Matsuda M, Tachiya K.
    J Clin Invest; 1977 Aug 15; 60(2):361-9. PubMed ID: 68962
    [Abstract] [Full Text] [Related]

  • 20. Structure of BbKI, a disulfide-free plasma kallikrein inhibitor.
    Zhou D, Hansen D, Shabalin IG, Gustchina A, Vieira DF, de Brito MV, Araújo AP, Oliva ML, Wlodawer A.
    Acta Crystallogr F Struct Biol Commun; 2015 Aug 15; 71(Pt 8):1055-62. PubMed ID: 26249699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.